1,721,089 research outputs found
Hypersideremic and hyperbilirubinemic effect of nicotinic acid in patients with Gilbert's syndrome
No full textHypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics
No full textThe authors conducted a clinical investigation in twenty-five patients affected with essential hypertension of mild or moderate grade associated with type II diabetes mellitus, the purpose being to assess the effect of 8 weeks of combined treatment with atenolol (100 mg) and chlorthalidone (25 mg) on arterial blood pressure, heart rate, and glycaemia. It is, indeed, generally known that both beta-blockade agents and diuretics can interfere with carbohydrate metabolism. The results indicate that 92% of the patients treated in this trial had significant reduction of systolic and diastolic blood pressure readings, in the absence of bradycardia or other adverse effects. Glycaemia values were lower at the end of treatment, probably as a result of better diet control during the trial, as suggested by the general tendency to body-weight reduction
[Electrocardiographic changes in myocardial damage; effect of treatment with nifedipine]
No full text[Nifedipine and essential arterial hypertension refractory to hypotensive therapy: results of a preliminary double-blind study]
No full textAbnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: the role of reduced affinity of the plasma membrane carrier of organic anions
No full textDiabetes mellitus after liver transplantation: a possible relation with the nutritional status
No full textSexual Dysfunction at the Onset of Type 2 Diabetes: The Interplay of Depression, Hormonal and Cardiovascular Factors
No full textIntroduction. Several data have emphasized the importance of early diagnosis of erectile dysfunction (ED) and
meticulous cardiovascular investigation in the type 2 diabetic mellitus (T2DM) patients.
Aim. To estimate the prevalence of ED and its associated determinants in a sample of male patients with new or
recently diagnosed T2DM.
Methods. The SUBITO-DE study is an observational, multicenter, prospective study involving 27 Italian diabetes
centers. Male patients recently diagnosed with T2DM were consecutively interviewed by their attending physician
at the diabetes care centers and asked whether they had experienced a change in their sexual function or found it
unsatisfactory. Those responding positively were then invited to participate in the study.
Main Outcome Measure. Several hormonal and biochemical parameters were studied.
Results. A nonselected series of 1,503 patients was interviewed, 499 of which (mean age, 58.8 ± 8.8 years) entered the
study, yielding a final enrolment rate of 33.3%. ED was classified as mild in 19.4%, mild-to-moderate in 15.4%,
moderate in 10.4%, and severe in 21.6% of patients, respectively. In addition, premature ejaculation, delayed
ejaculation, and hypoactive sexual desire (HSD) were comorbid in 28.3%, 32.9%, and 58.4%, respectively. Finally,
hypogonadism, showed an estimated prevalence of almost 20%. Both organic (at least one chronic DM-associated
complication) and psychological factors (severe depressive symptoms) increased the risk of ED. Severe depressive
symptoms were also associated with ejaculatory problems, HSD, and hypogonadism.
Conclusions. A high prevalence of sexual dysfunction in men with recently diagnosed T2DM was detected. Early
diagnosis of ED could help prevent emotional and physical discomfort in men and aid in identifying reversible
cardiovascular risk factors. Screening of sexual dysfunction should become a part of routine care in the management
of T2DM patients
"Liver cell Storage (S) and Maximum Transport (TM) of BSF in Liver Cirrhosis and Chronic Hepatitis"
No full textInfluence of allopurinol on the half-life of tolbutamide and rifamycin-SV in blood of healthy volunteers
No full textThe influence of treatment with allopurinol (5 mg/kg/die for 15 days) on T/2 of tolbutamide and rifomycin-SV intravenously administered, has been studied in 10 healthy volunteers. We have observed reduction of T/2 of tolbutamide and, on the contrary, prolongation of T/2 of rifamycin-SV. Tolbutamide behaviour was unexpected, considering that other Authors had previously found inhibition of metabolic degradation of other drugs metabolized by the microsomal enzymes. We conclude that data concerning the influence of a drug (in our case, allopurinol) on the metabolism of another drug cannot always authorize general deduction and previsions regarding the metabolic interferences on the pharmacokinetics of other substances
- …
